Neuranics, a healthcare diagnostics startup, has raised $700,000 in its seed funding round led by Inflection Point Ventures (IPV).
The funds will be used to advance technology development, and clinical validation, and prepare the company for commercial production post-CDSCO licensing.
Praveen Kumar Bhagat, Co-founder and CEO of Neuranics, said, “We are re-imagining how we approach diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising on the quality. Our technology empowers clinicians with real-time data, transforming care delivery and elevating patient outcomes. By leveraging AI on de-identified pathological imaging data generated by our analyzer, we aim to set a new gold standard for national screening programs. This innovative technology will elevate healthcare quality in India and establish the country as a global leader in point-of-care blood analyser. We thank IPV for being with us in this journey. Working with IPV has been a streamlined and transformative experience. Their investment and guidance have empowered us to scale faster, innovate further, and bring our vision to life. IPV’s efficient processes and industry connections have been instrumental in our journey.”
Dr Megha Sharma, MD Pathologist and Chief Medical Evangelist at Neuranics, said, “Our point-of-care CBC analyzer represents a significant leap forward in diagnostic convenience and accessibility. By utilizing a simple finger-prick capillary blood sample. We have effectively eliminated the need for traditional venipuncture, making blood testing faster, less invasive, and more patient-friendly. This technology empowers healthcare providers to deliver immediate, actionable insights, even in resource-limited settings, ultimately improving patient outcomes especially in Primary health care centres for screening and at emergency setups for triage.”
Mitesh Shah, Co-founder of IPV, said, “Neuranics is tackling the problem of lengthy and complex blood testing processes with their point-of-care blood analyzer that makes complete blood count diagnosis faster and easier. This significantly improves patient care, especially in urgent cases. IPV believes in the startups innovative technology and envisions a future where the startups bring out more such necessary tools.”
Founded in 2021 by Praveen Kumar Bhagat (Co-founder and CEO) and Ashutosh Patra (Co-founder and CTO), Neuranics is developing a point-of-care blood analyzer capable of delivering complete blood count (CBC) results in less than 10 minutes using just a finger-prick sample. The device, designed for primary and emergency settings, offers low maintenance and high efficiency, making it a game-changer for the healthcare industry.
Having accurate CBC results available immediately at the point of care, while the physician is still with the patient, allows for better-informed decisions regarding triage, additional testing, and treatment as delays are no longer caused by transport and preparation of clinical samples.
At the same time, life-saving treatments for critical conditions like sepsis, severe anemia, and thrombocytopenia, especially in dengue patients, can be initiated promptly, ensuring timely and effective care.
The company has achieved milestones, including a patent granted, receiving the CDSCO Test License, Ethical Approval from AIIMS Delhi, and progressing through clinical trials. Neuranics also gained recognition at Yourstory Tech30, Amazon-Sambhav, and India-Sweden Innovation Challenge for its potential to decentralize routine diagnostics, offering quicker and more accessible screening for conditions such as anemia, thalassemia, malaria, and leukemia.
